Zusammenfassung

Decline of body weight with aging is a major risk factor for frailty, osteoporosis and fracture, suggesting that treatment for osteoporosis may affect body composition. However, the effects of treatment for osteoporosis on body composition are not well known. The present study aimed to identify the relationship between treatment for osteoporosis and body composition markers. We measured bone mineral density (BMD), body composition, and bone remodeling markers in 551 Japanese postmenopausal women with Selective estrogen receptor modulators (SERMs) (SERM treatment group; N = 143) treatment, with bisphosphonates treatment (BP treatment group; N = 193) and without treatment by any osteoporosis drug (No treatment group; N = 358) for 4 to 7 years (mean observation periods; 5.5 years) and analyzed the relationship of these with BMD, body mass index (BMI), body weight, and biochemical markers. The mean (SD) age of the participants was in 68.9 (9.3) year SERM treatment group, 68.6 (9.8) year in BP treatment group and 63.7 (10.6) year in No treatment group. Percent-changes in body weight and BMI were significantly different between women taking SERMs or BPs and those not taking any osteoporosis drugs (P < 0.01 and < 0.01, respectively). In multiple linear regression analysis, SERMs and BPs treatment was a significant independent determinant of body weight and BMI. Long-term use of SERMs and BPs may prevent reductions in BMI and body weight, usually observed in elderly women.